China has taken a significant step in the global race to commercialise brain-computer interface (BCI) technology, with researchers describing it as the world’s first commercially available implantable brain chip, ahead of Elon Musk’s Neuralink.
The device, known as NEO, was developed by Shanghai-based Neuracle Medical Technology and has received regulatory approval for use in patients with spinal cord injuries and paralysis following successful clinical trials.
The approval makes China the first country to commercially authorise an invasive brain-computer interface for medical use, which marks a milestone in neurotechnology.
The development puts China ahead of Neuralink in commercial deployment. While Neuralink has successfully implanted its devices in a limited number of human trial participants and continues clinical testing in the United States, it has not yet received approval for broad commercial use.
How China’s NEO Differs from Neuralink
NEO uses electrodes positioned on the brain’s protective outer membrane (the dura mater), which makes it less invasive than Neuralink’s system, which inserts ultra-thin electrode threads directly into brain tissue.
This less invasive design may have helped accelerate regulatory approval while reducing surgical risks, although it may involve different performance trade-offs.
Although both systems seek to translate brain signals into digital commands, they take different technological approaches.
The Chinese implant is designed primarily to help people with paralysis regain movement by controlling external devices such as robotic assistive equipment using thought alone.
Neuralink has broader long-term ambitions that include restoring movement, speech and vision, while eventually enabling high-bandwidth communication between humans and computers.
More than a medical breakthrough
China’s achievement signals the country’s growing ambition to dominate emerging technologies that are expected to shape future industries alongside artificial intelligence, robotics and advanced semiconductors.
The Chinese government has designated brain-computer interfaces as a strategic industry and has increased investment, clinical research and regulatory support to speed commercial adoption.
Analysts estimate China’s BCI market could expand rapidly over the next few years as medical applications mature.
The approval also intensifies technological competition between China and the United States in a field that many researchers believe could become as transformative as smartphones or Artificial Intelligence.
What it means
The commercial approval of NEO reflects that the race in brain-computer interfaces is no longer defined solely by technological innovation but also by the ability to move discoveries from laboratories into hospitals.
For patients living with paralysis, the breakthrough could provide earlier access to life-changing assistive technologies.
For investors and technology companies, this highlights that success in neurotechnology will depend not only on engineering advances but also on regulation, manufacturing capacity and healthcare integration.
Similarly, widespread deployment of brain implants raises important ethical questions around data privacy, cybersecurity, informed consent and the ownership of neural data but as governments and companies push to commercialise the technology, regulators will face increasing pressure to establish safeguards that protect users while encouraging innovation.
China’s approval of NEO may not mean the country has surpassed Neuralink in every technical aspect, but it does mark the first major victory in the race to bring implantable brain-computer interfaces to the commercial market.
Join BusinessDay whatsapp Channel, to stay up to date
Open In Whatsapp
